Trial Search Results

Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery

Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. We currently have few medications to prevent this kidney injury. The hypothesis of this study is that giving aminophylline after heart surgery can decrease the acute kidney injury.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: Aminophylline
  • Drug: Placebo

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Less than 18 years old, undergoing cardiac surgery with bypass

   - neonates must be at least 36 weeks gestational age

Exclusion Criteria:

   - History of arrythmia or seizure, on extracorporeal membrane oxygenation (ECMO)
   support, already taking aminophylline/theophylline, liver failure, sepsis, on renal
   replacement therapy

Ages Eligible for Study

N/A - 18 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
David M Axelrod, MD
Not Recruiting